Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22708531 | 0.96 | PTGER4 (0.32) | MAPTKDM4ETSHRLMNAMAPK1 | |
| SCHEMBL21668946 | 0.91 | ALDH1A1 (0.34) | MAPTKDM4ETSHRLMNAMAPK1 | |
| SCHEMBL22708734 | 0.90 | PGR (0.32) | — | |
| SCHEMBL22708506 | 0.90 | MAPT (0.34) | MAPTKDM4ETSHRLMNAMAPK1 | |
| SCHEMBL21863124 | 0.88 | PTGER4 (0.33) | MAPTKDM4ETSHRMAPK1HSD17B10 | |
| SCHEMBL21883297 | 0.88 | ALDH1A1 (0.32) | MAPTKDM4ETSHRLMNAMAPK1 | |
| SCHEMBL22708354 | 0.88 | TSHR (0.33) | MAPTKDM4ETSHRLMNAMAPK1 | |
| SCHEMBL21740464 | 0.87 | TSHR (0.35) | MAPTKDM4ETSHRLMNAMAPK1 | |
| SCHEMBL27444621 | 0.87 | TSHR (0.31) | KDM4ETSHRHSD17B10ALDH1A1POLB | |
| SCHEMBL15785856 | 0.87 | ALDH1A1 (0.34) | MAPTKDM4ETSHRLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11588110-B2 | Heterocyclic compound and organic light emitting device comprising the same | LT MATERIALS CO., LTD. (KR) | 2023-02-21 | — | — | US | disclosed |
| US-20200373499-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | LT MATERIALS CO., LTD. (KR) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11588110-B2 | Heterocyclic compound and organic light emitting device comprising the same | CRY1, CYP1A1, CYP1B1 | MAPT 1801/4885KDM4E 2866/4885TSHR 3861/4885 |
| US-20200373499-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | CRY1, CYP1A1, CYP1B1 | MAPT 1801/4885KDM4E 2866/4885TSHR 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.